Form 4: Emergent BioSolutions Executive Sells Shares
Statement of Changes in Beneficial Ownership
Emergent BioSolutions SVP Paul Anthony Williams reported a sale of 4,000 shares of common stock on April 1, 2026, executed under a pre-arranged trading plan.
Summary
- Paul Anthony Williams, SVP, Products Business at Emergent BioSolutions Inc. (EBS), reported a transaction on April 1, 2026.
- The transaction involved the sale of 4,000 shares of common stock.
- These shares were sold at a weighted average price of $8.44, with individual sales ranging from $8.34 to $8.54.
- The sale was conducted under a Rule 10b5-1(c) trading plan adopted on November 14, 2025.
- Following the transaction, Williams beneficially owns 62,681 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing. While an executive sale can sometimes be perceived negatively, the execution under a pre-established 10b5-1 plan mitigates concerns about insider trading based on non-public information.
Negatives
- An executive sold a portion of their holdings in the company.
Future Outlook
No specific future outlook or guidance is provided in this filing, as it pertains to a change in beneficial ownership.
Management Comments
- The sale was made pursuant to a trading plan adopted on November 14, 2025, intended to comply with Rule 10b5-1(c).
- The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan indicates a structured approach to stock sales, often employed by executives to diversify holdings or manage personal finances without appearing to trade on material non-public information.
Stakeholder Impact
- Shareholders: The sale of shares by an executive may be monitored, but the use of a 10b5-1 plan suggests a planned, rather than opportunistic, divestment.
Key Dates
| Date | Description |
|---|---|
| 2025-11-14 | Date trading plan adopted by Reporting Person. |
| 2026-04-01 | Transaction Date for sale of common stock. |
| 2026-04-03 | Date of filing for Form 4. |
Keywords
Emergent BioSolutions, EBS, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Executive Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.